UHS Stock Analysis: Universal Health | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 10.541m USD | 12M Return: -14.1% | US9139031002 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 132M
EPS Trend: 98.6%
Qual. Beats: 1
Rev. Trend: 99.9%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Universal Health Services, Inc. (NYSE: UHS) is a U.S. health care company that owns and operates acute care hospitals alongside outpatient and behavioral health care facilities through two reporting segments: Acute Care Hospital Services and Behavioral Health Care Services. Its hospitals deliver a broad range of services, including general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatrics, pharmacy, and behavioral health. Beyond direct patient care, the company offers commercial health insurance products, capital resources, and centralized management services such as purchasing, information systems, finance, facilities planning, physician recruitment, and marketing. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, UHS has been listed on the NYSE since 1990 and is classified as a large-cap stock within the Health Care Facilities sub-industry.
UHS is differentiated from many large hospital operators, such as HCA Healthcare and Tenet Healthcare, by the scale of its behavioral health segment, which has historically accounted for a significant share of its facility count and revenue. Behavioral health services have benefited from rising demand tied to expanded insurance coverage for mental health and substance use treatment, a structural tailwind that has supported the segments growth relative to the more mature acute care hospital industry.
- Behavioral health segment drives revenue growth through facility expansion
- Acute care margins pressured by rising labor and nurse staffing costs
- Medicaid reimbursement rate changes impact hospital revenue mix
| Net Income: 1.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 2.11% < 20% (prev 4.09%; Δ -1.98% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.80b > Net Income 1.53b |
| Net Debt (5.53b) to EBITDA (2.82b): 1.96 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.9m) vs 12m ago -7.77% < -2% |
| Gross Margin: 90.69% > 18% (prev 90.17%; Δ 0.51% > 0.5%) |
| Asset Turnover: 117.2% > 50% (prev 109.8%; Δ 7.33% > 0%) |
| Interest Coverage Ratio: 13.99 > 6 (EBIT TTM 2.18b / Interest Expense TTM 155.7m) |
| A: 0.02 (Total Current Assets 3.68b - Total Current Liabilities 3.30b) / Total Assets 15.9b |
| B: 0.52 (Retained Earnings 8.26b / Total Assets 15.9b) |
| C: 0.14 (EBIT TTM 2.18b / Avg Total Assets 15.5b) |
| D: 0.91 (Book Value of Equity 7.51b / Total Liabilities 8.28b) |
| Altman-Z'' = 3.75 = AA |
| DSRI: 1.11 (Receivables 2.80b/2.30b, Revenue 18.1b/16.5b) |
| GMI: 0.99 (GM 90.17% / 90.69%) |
| AQI: 0.95 (AQ_t 0.30 / AQ_t-1 0.32) |
| SGI: 1.10 (Revenue 18.1b / 16.5b) |
| TATA: -0.02 (NI 1.53b - CFO 1.80b) / TA 15.9b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of October 05, 2026, the stock is trading at USD 175.72 with a total of 597,902 shares traded. Over the past week, the price has changed by -1.76%, over one month by +4.91%, over three months by +11.11% and over the past year by -14.14%.
Current recommended Stop Loss: 169.00 (which is 3.8% or 1.3 ATR below the current price).
Universal Health has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold UHS.
- StrongBuy: 6
- Buy: 2
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 194.4 | 10.6% |
P/E Trailing = 7.3004
P/E Forward = 7.2569
P/S = 0.5819
P/B = 1.4063
P/EG = 1.2093
Revenue TTM = 18.1b USD
EBIT TTM = 2.18b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 4.08b USD (from longTermDebt, last quarter)
Short Term Debt = 842.8m USD (from shortTermDebt, last quarter)
Debt = 5.67b USD (from shortLongTermDebtTotal, last quarter) + Leases 410.3m
Net Debt = 5.53b USD (calculated: Debt 5.67b - CCE 138.8m)
Enterprise Value = 16.1b USD (10.5b + Debt 5.67b - CCE 138.8m)
Interest Coverage Ratio = 13.99 (Ebit TTM 2.18b / Interest Expense TTM 155.7m)
EV/FCF = 19.44x (Enterprise Value 16.1b / FCF TTM 826.7m)
FCF Yield = 5.14% (FCF TTM 826.7m / Enterprise Value 16.1b)
FCF Margin = 4.56% (FCF TTM 826.7m / Revenue TTM 18.1b)
Net Margin = 8.42% (Net Income TTM 1.53b / Revenue TTM 18.1b)
Gross Margin = 90.69% ((Revenue TTM 18.1b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 90.87% (prev 90.51%)
Tobins Q-Ratio = 1.01 (Enterprise Value 16.1b / Total Assets 15.9b)
Interest Expense / Debt = 2.75% (Interest Expense 155.7m / Debt 5.67b)
Taxrate = 23.51% (476.4m / 2.03b)
NOPAT = 1.67b (EBIT 2.18b * (1 - 23.51%))
Current Ratio = 1.12 (Total Current Assets 3.68b / Total Current Liabilities 3.30b)
Debt / Equity = 0.75 (Debt 5.67b / totalStockholderEquity, last quarter 7.51b)
Debt / EBITDA = 1.96 (Net Debt 5.53b / EBITDA 2.82b)
Debt / FCF = 6.69 (Net Debt 5.53b / FCF TTM 826.7m)
Total Stockholder Equity = 7.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.87% (Net Income 1.53b / Total Assets 15.9b)
RoE = 20.66% (Net Income TTM 1.53b / Total Stockholder Equity 7.39b)
RoCE = 19.00% (EBIT 2.18b / Capital Employed (Equity 7.39b + L.T.Debt 4.08b))
RoIC = 12.49% (NOPAT 1.67b / Invested Capital 13.3b)
WACC = 6.03% (E(10.5b)/V(16.2b) * Re(8.14%) + D(5.67b)/V(16.2b) * Rd(2.75%) * (1-Tc(0.24)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.27 | Cagr: -5.75%
[DCF] Terminal Value 74.23% ; FCFF base≈856.6m ; Y1≈800.3m ; Y5≈733.8m
[DCF] Fair Price = 117.3 (EV 11.6b - Net Debt 5.53b = Equity 6.06b / Shares 51.7m; r=8.35% [WACC [floored]]; 5y FCF grow -8.30% → 2.50% )
EPS Correlation: 98.61 | EPS CAGR: 37.35% | SUE: 0.87 | # QB: 1
Revenue Correlation: 99.94 | Revenue CAGR: 9.97% | SUE: 0.93 | # QB: 2
EPS current Quarter (2026-09-30): EPS=5.21 | Chg30d=+0.36% | Revisions=-80% | Analysts=15
EPS current Year (2026-12-31): EPS=22.59 | Chg30d=+0.20% | Revisions=-56% | GrowthEPS=+3.9% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=24.00 | Chg30d=-0.55% | Revisions=-69% | GrowthEPS=+6.2% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -78% (up=3, down=35)